anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the titled composition having long-acting antibacterial activity, and suitable for the manufacture of a molded latex product such as medical tools, hygienic parts, etc., by compounding the latex of natural rubber or synthetic polymer with a hardly water-soluble biguanide compound or its salt. CONSTITUTION:A natural rubber latex or synthetic polymer latex is compounded with a hardly water-soluble biguanide compound, e.g. the compound of formula I or formula II (R is alkyl, phenyl, etc.; R' is H or alkyl; n is positive integer), preferably 1,6-di-(4-chlorophenylbiguanide)hexane. A stable composition can be obtained without causing gelation. The content of the biguanide compound is preferably 0.1-10wt% based on the latex. It is applied in the molding of a medical tools, hygienic parts, food preparation machines, etc. necessary to keep continuous antibacterial activity even in using over a long period. Especially, the urethral infection can be prevented effectively by using the composition in a urinary catheter.
The composition, according to the utility model, will find application for the treatment of wounds caused by external factors and is also suitable for the treatment of certain chronic wounds, such as decubitus ulcers and milder forms of diabetic foot syndrome and lower leg ulcers. The composition of the gel for wound healing contains c / wt. % / bioactive composition, which is a mixture of yeast hydrolysates from Saccharomyces cerevisiae, allantoin, gelatin hydrolyzate, calendula extract (Calendula officinalis), plantain leaf extract (Plantago major), the bioactive composition being in an amount of 20 to 25 , aqueous extract of mucus of garden snails Helix aspersa in an amount of 25 to 35, ingredients in an amount of 12 to 14, preservative in an amount of 1 to 2 and deionized water up to 100. The composition, according to the utility model, provides a high regenerating effect. The application of the gel does not cause side effects. The treatment of the affected areas with the gel leads to complete healing of the wounds.
Control group: Basic therapy - 160 patients, retrospective enrollment. Basic therapy is the routine practice of the institution for the treatment of patients with sepsis (conservative anti-infective therapy). Antibacterial therapy regimens, antibiotic dosage adjustment regimens for AKI and prolonged RRT procedures are not specifically prescribed in the CT Plan.
In a clinical safety trial conducted in children aged 2 to 16 years (mean 7.4 years), following induction with another agent, SUPRANE and isoflurane (in N2O/O2) were compared when delivered via face mask or laryngeal mask airway (LMA™ mask) for maintenance of anesthesia, after induction with intravenous propofol or inhaled sevoflurane, in order to assess the relative incidence of respiratory adverse events.

SUPRANE was associated with higher rates (compared with isoflurane) of coughing, laryngospasm and secretions with an overall rate of respiratory events of 39%. Of the pediatric patients exposed to desflurane, 5% experienced severe laryngospasm (associated with significant desaturation; i.e. SpO2 of <90% for >15 seconds, or requiring succinylcholine), across all ages, 2-16 years old. Individual age group incidences of severe laryngospasm were 9% for 2-6 years old, 1% for 7-11 years old, and 1% for 12-16 years old. Removal of LMA™ mask under deep anesthesia (MAC range 0.6 – 2.3 with a mean of 1.12 MAC) was associated with a further increase in frequency of respiratory adverse events as compared to awake LMA™ mask removal or LMA™ mask removal under deep anesthesia with the comparator. The frequency and severity of non-respiratory adverse events were comparable between the two groups.

The incidence of respiratory events under these conditions was highest in children aged 2-6 years. Therefore, similar studies in children under the age of 2 years were not initiated.
Recent studies confirm the critical roles of endoplasmic reticulum oxidoreductase 1 alpha (ERO1L) in malignant behavior of various cancers. Nevertheless, what function ERO1L plays in lung adenocarcinoma (LUAD) remains uncovered. The expressions and clinical significance of ERO1L in LUAD were investigated using the TCGA dataset. The ERO1L levels were examined by RT-qPCR. The LUAD cell proliferation was valued using colony formation as well as CCK-8 assays. The invasion and migration abilities of LUAD cells were detected through Transwell in addition to wound healing assays. The effects of ERO1L on LUAD cell apoptosis were determined by flow cytometric analysis. Moreover, we also established mouse xenograft models of LUAD cells to confirm the functions of ERO1L in vivo. The ERO1L levels in tumors were identified by immunohistochemistry. Western blot was used for the detection of the levels of Wnt/βcatenin signaling-related proteins. The TCGA database revealed that ERO1L expressions were higher in LUAD tissues than those in non-cancerous tissues. ERO1L overexpression was related to poorer overall survival of LUAD patients. In addition, ERO1L silence suppresses LUAD cell clone formation, proliferation, migration as well as invasion but induces apoptosis. Moreover, we also verified that ERO1L silence could promote LUAD growth in vivo. Based on the mechanism analysis, ERO1L was confirmed to regulate LUAD development via Wnt/βcatenin cascade signal. ERO1L, the expression of which was increased in LUAD tissues, functioned as an oncogene. ERO1L silence significantly attenuated LUAD tumorigenesis, likely via inhibition of Wnt/βcatenin signaling, indicating that ERO1L could be exploited as a promising biomarker in LUAD treatment.
The present invention is an apparatus and a method for delivery of mitomycin through an eluting biocompatible implantable medical device (99). A biocompatible drug release matrix comprises a biocompatible drug release matrix and a drug (55) incorporated into the biocompatible drug release matrix. The drug (55) has antibiotic and anti-proliferative properties and is an analogue related to the quinone-containing alkylating agents of a mitomycin family. The drug (55) is initially released from the biocompatible drug release matrix at a faster rate followed by a release at a slower rate. The drug (55) release rate maintains tissue level concentrations of the drug (55) for at least two weeks after implantation of the medical device (99). The present invention provides a coating for a vascular prosthesis that elutes the drug (55) at a controlled rate to inhibit proliferation of smooth muscle cells causing restenosis.
<P>PROBLEM TO BE SOLVED: To provide a composition which reduces the onset risk of colon cancer, liver cancer, pancreas cancer, bile duct cancer and cholelithiasis by ingestion thereof as an ordinary foods and drinks.  <P>SOLUTION: The secondary bile acid inhibitor comprises bacteria belonging to the genus Ruminococcus and/or difructose dianhydride 3 (di-D-fructofuranose-1,2':2,3'-dianhydride, abbreviated as DFAIII). Foods and drinks and animal foods containing the inhibitor are also provided. The secondary bile acid inhibitor comprising raffinose, melibiose or fructooligosaccharide in addition to the combination above is also provided. Foods and drinks and animal foods containing the inhibitor are also provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Although real-world studies have found that remdesivir is effective in preventing poor prognosis, more information is needed on the optimal timing of remdesivir administration in high-risk coronavirus disease 2019 (COVID-19) patients in the Omicron era. From February 2022 to January 2023, a single-center retrospective study was performed in Korea. We compared the clinical characteristics and treatment outcomes between early (remdesivir treatment within 0-3 days from symptom onset) and late (≥ 4 days from symptom onset) treatment groups of patients who received remdesivir monotherapy. Of 284 patients, 225 were classified into the early treatment group and 59 were classified into the late treatment group. The early treatment group had a lower rate of 28-day progression to severe disease than the late treatment group (1.4% vs 7.4%, P = .03). Delaying remdesivir treatment ≥ 4 days from symptom onset (adjusted odds ratio [aOR], 6.17; 95% CI, 1.18-32.44; P = .03) and Charlson comorbidity index ≥ 3 (aOR, 9.62; 95% CI, 1.65-56.10; P = .01) were independent risk factors for 28-day progression to severe disease. Our results suggest that early administration of remdesivir could be associated with better prognosis in COVID-19 patients with the Omicron variant, and within 3 days from symptom onset seems to be the appropriate timing.
Ipratropium Bromide Nasal Solution, 0.03% is intended to relieve your rhinorrhea (runny nose) with regular use. It is therefore important that you use Ipratropium Bromide Nasal Solution, 0.03% as prescribed by your physician. For most patients, some improvement in runny nose is usually apparent during the first full day of treatment with Ipratropium Bromide Nasal Solution, 0.03%. Some patients may require up to two weeks of treatment to obtain maximum benefit. 

Do not spray Ipratropium Bromide Nasal Solution, 0.03% in your eyes. Should this occur, immediately flush your eye with cool tap water for several minutes. If you accidentally spray Ipratropium Bromide Nasal Solution, 0.03% in your eyes, you may experience a temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion, development or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. Should acute eye pain or blurred vision occur, contact your doctor. 

Should you experience excessive nasal dryness or episodes of nasal bleeding, contact your doctor. 

If you have glaucoma or difficulty urinating due to an enlargement of the prostate, be sure to tell your physician prior to using ipratropium bromide nasal solution 0.03%. . 

If you are pregnant or you are breast feeding your baby, be sure to tell your physician prior to using ipratropium bromide nasal solution 0.03%.

Address medical inquiries to Northstar Rx LLC at 1-800-206-7821.

Storage 

Store tightly closed at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Avoid freezing. Keep out of reach of children. 

December 2021
Chronic and elevated levels of the antiviral cytokine IFN-α in the brain are neurotoxic. This is best observed in patients with genetic cerebral interferonopathies such as Aicardi-Goutières syndrome. Cerebral interferonopathies typically manifest in early childhood and lead to debilitating disease and premature death. There is no cure for these diseases with existing treatments largely aimed at managing symptoms. Thus, an effective therapeutic strategy is urgently needed. Here, we investigated the effect of antisense oligonucleotides targeting the murine IFN-α receptor (Ifnar1 ASOs) in a transgenic mouse model of cerebral interferonopathy. Intracerebroventricular injection of Ifnar1 ASOs into transgenic mice with brain-targeted chronic IFN-α production resulted in a blunted cerebral interferon signature, reduced neuroinflammation, restoration of blood-brain barrier integrity, absence of tissue destruction, and lessened neuronal damage. Remarkably, Ifnar1 ASO treatment was also effective when given after the onset of neuropathological changes, as it reversed such disease-related features. We conclude that ASOs targeting the IFN-α receptor halt and reverse progression of IFN-α-mediated neuroinflammation and neurotoxicity, opening what we believe to be a new and promising approach for the treatment of patients with cerebral interferonopathies.
In certain aspects, the present disclosure provides an enzyme inhibitory nanoparticle. The nanoparticle may comprise zinc oxide. The nanoparticle exhibits substantially reversible enzyme inhibition in the presence of an enzyme. In certain aspects, the shape of the nanoparticle may be a nanopyramid or a nanoplate/nanodisc. In other aspects, the present disclosure provides an antimicrobial material comprising a layer-by-layer (LBL) coating comprising a plurality of nanoparticles comprising zinc oxide. Each nanoparticle exhibits antimicrobial activity in the presence of bacteria. LBL coatings of ZnO-NP reduced  Staphylococcal  biofilm burden by > 95%. The disclosure also provides methods of preparing an enzyme inhibitory or antimicrobial nanoparticles comprising zinc oxide.
Detecting chromosome structural abnormalities in medical genetics is essential for diagnosing genetic disorders and understanding their implications for an individual's health. However, existing computational methods are formulated as a binary-class classification problem trained only on representations of positive/negative chromosome pairs. This paper introduces an innovative framework for detecting chromosome abnormalities with banding resolution, capable of precisely identifying and masking the specific abnormal regions. We highlight a pixel-level abnormal mapping strategy guided by banding features. This approach integrates data from both the original image and banding characteristics, enhancing the interpretability of prediction results for cytogeneticists. Furthermore, we have implemented an ensemble approach that pairs a discriminator with a conditional random field heatmap generator. This combination significantly reduces the false positive rate in abnormality screening. We benchmarked our proposed framework with state-of-the-art (SOTA) methods in abnormal screening and structural abnormal region segmentation. Our results show cutting-edge effectiveness and greatly reduce the high false positive rate. It also shows superior performance in sensitivity and segmentation accuracy. Being able to identify abnormal regions consistently shows that our model has demonstrated significant clinical utility with high model interpretability. BRChromNet is open-sourced and available at https://github.com/frankchen121212/BR-ChromNet.
The present invention discloses a rapid-acting hair promoting liquid which is prepared by that fleece-flower roots, camphor, cortex cinnamomi, myrobalan, prepared rhizome of rehmannia, licorice roots and sesame oil are crushed, immersed, pressed and filtered according to certain weight part proportioning. Through clinical tests, the present invention has particular treating effects on alopecia seborrheica, alopecia areata and various sequelaes caused by dyeing hairs for a long time. In particular, the present invention has obvious hair growing and hair blacking effects on hair follicle cellular atrophy or necrosis. The present invention can obtain hair growing and hair building effects on the alopecia after radiotherapy and chemotherapy for various cancer within 7 to 15 days after patients take the medicine. Through the verification of clinical nodulus of 133 cases, the total effective rate for various symptoms is above 98 %. The rapid-acting hair promoting liquid of the present invention has the advantages of wide medical resources, low price, simple preparation, easy use, safety and reliability, is suitable for industrialization scale production, and is suitable for treating various alopecia or patients who suffer from alopecia areata.
The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
PURPOSE: To obtain a preparation composition for external use, containing an extract of the genus Tournefortia plant in the family Boraginaceae as an active ingredient, having an excellent antiinflammatory action and an antipruritic action, improved in safety, and used for cosmetics, medicines, etc., for preventing or improving inflammation, itch, skin roughness, etc. CONSTITUTION: This composition for external use contains as an active ingredient an extract obtained by extracting a Boraginaceae Tournefortia plant such as Tournefortia sarmentosa Lam. or Tournefortia montana Lour. with a solvent such as water, a neutral polar solvent (e.g. ether, chloroform, ethyl acetate, acetone) or a (polyhydric) lower alcohol (e.g. a 1-4C monohydric alcohol, a glycol, glycerol). The extract is obtained e.g. by immersing the leaves or roots of the Tournefortia montana Lour. in a 1-30 times amount of an extraction solvent at the ordinary temperature or 50-80 deg.C for 1-8hrs once to several times, subjecting the obtained extract to a filtration or centrifugal separation treatment to remove the solid contents, removing the extraction solvent, and, if necessary, further concentrating and drying the product.
OBJECTIVES: Drowning is the leading cause of death during flood disasters. Little is known about these deaths. Child death review teams review details of child deaths to understand circumstances and risk factors to inform prevention.
METHODS: Using data entered in 2005 to 2021 for children ages 0 to 17 years from the National Fatality Review-Case Reporting System, we identified 130 drowning deaths directly attributed to natural disaster or weather incidents, and 14 deaths indirectly attributed to these incidents. Frequencies, proportions, and χ2 statistics were used to describe selected measures and compare with other drowning deaths.
RESULTS: Children who drowned as a direct result of a natural disaster- or weather-related incident were more likely to be aged >4 years (81% vs 40%, P < .001) and located in a rural or frontier setting (63% vs 30%, P < .001). They were more likely to be supervised at the time of the incident (61% vs 38%, P < .001), and it was more likely for additional children (35% vs 5%, P < .001) or adults (33% vs 3%, P < .001) to have perished. The indirect deaths were commonly a result of damage to protective barriers.
CONCLUSIONS: The characteristics of natural disaster- or weather-related drowning deaths among children differ from other drowning deaths. Natural disaster- or weather-related drowning may warrant tailored drowning prevention strategies. Improved surveillance of all water-related deaths may be a proactive action leading to the development of these prevention strategies, whereas poststorm remediation of protective barriers can be used as a reactive prevention after a storm has passed.
This is a mucosal thermo-destruction technique. It uses a generator that delivers a sinusoidal current of high frequency to a probe covered with bipolar electrodes in tight network ensuring a uniform diffusion of the thermal effect. The tissue penetration is superficial on 1mm, intended to eradicate the epithelium up to the muscularis mucosae. Circumferential or focal probes are used as a function of the length of the segment to be treated.
The EVD will be set to an initial level of 5 mmHg. The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
Levofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested [see Warnings and Precautions (5.12)]. In immature dogs (4 to 5 months old), oral doses of 10 mg/kg/day for 7 days and intravenous doses of 4 mg/kg/day for 14 days of levofloxacin resulted in arthropathic lesions. Administration at oral doses of 300 mg/kg/day for 7 days and intravenous doses of 60 mg/kg/day for 4 weeks produced arthropathy in juvenile rats. Three-month old beagle dogs dosed orally with levofloxacin at 40 mg/kg/day exhibited clinically severe arthrotoxicity resulting in the termination of dosing at Day 8 of a 14-day dosing routine. Slight musculoskeletal clinical effects, in the absence of gross pathological or histopathological effects, resulted from the lowest dose level of 2.5 mg/kg/day (approximately 0.2-fold the pediatric dose based upon AUC comparisons). Synovitis and articular cartilage lesions were observed at the 10 and 40 mg/kg dose levels (approximately 0.7-fold and 2.4-fold the pediatric dose, respectively, based on AUC comparisons). Articular cartilage gross pathology and histopathology persisted to the end of the 18-week recovery period for those dogs from the 10 and 40 mg/kg/day dose levels. 

When tested in a mouse ear swelling bioassay, levofloxacin exhibited phototoxicity similar in magnitude to ofloxacin, but less phototoxicity than other quinolones. 

While crystalluria has been observed in some intravenous rat studies, urinary crystals are not formed in the bladder, being present only after micturition and are not associated with nephrotoxicity. 

In mice, the CNS stimulatory effect of quinolones is enhanced by concomitant administration of non-steroidal anti-inflammatory drugs. 

In dogs, levofloxacin administered at 6 mg/kg or higher by rapid intravenous injection produced hypotensive effects. These effects were considered to be related to histamine release. 

In vitro and in vivo studies in animals indicate that levofloxacin is neither an enzyme inducer nor inhibitor in the human therapeutic plasma concentration range; therefore, no drug metabolizing enzyme-related interactions with other drugs or agents are anticipated.
The present invention provides new methods for the assessment of cancer risk in the general population. These methods utilize particular alleles of two or more genes, in combination, to identify individuals with increased or decreased risk of cancer. Exemplified is risk assessment for breast cancer in women. In addition, personal history measures such as age and race are used to further refine the analysis. Using such methods, it is possible to reallocate healthcare costs in cancer screening to patient subpopulations at increased cancer risk. It also permits identification of candidates for cancer prophylactic treatment.
This is a phase III prospective study with the primary objective to compare the efficacy and safety of HIPEC. The target population for this study is patients with primary or recurrence ovarian, peritoneal or fallopian tube cancers undergoing CRS. 'Platinum-sensitive' recurrence is defined as recurrence 6 months after the completion of the primary platinum-based chemotherapy. A single dose of lobaplatin 40mg/m2 will be administered via HIPEC , and will be administered at the time of surgery, 3 days after surgery and 5 days after surgery. Patients of group A will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy (carboplatin and paclitaxel, carboplatin and gemcitabine, or carboplatin and liposomal doxorubicin) for 6 cycles. Patients of group B will undergo CRS and then go on to intravenous chemotherapy.
PURPOSE:To provide a testosterone 5alpha-reductase inhibitor useful as a trichogen or a preventive for pimple, seborrheic alopecia, dandruff, etc., and containing an extracted aglycon produced by using the reaction of baicalinase which is an enzyme existing in OUGON (a herb drug). CONSTITUTION:The objective testosterone 5alpha-reductase inhibitor contains an aglycon originated from OUGON (root of Scutellaria baicalensis known as a herb drug) and extracted by utilizing the reaction of baicalinase which is an enzyme existing in OUGON. The inhibitor is applicable to drugs, quasi-drugs and cosmetics. It is expected as a trichogen to be applied to the scalp or skin. The agent is effective in improving the seborrheic state by controlling the sebum secretion function of the scalp and skin and preventing the pimple, seborrheic alopecia and accompanying dandruff, etc. The agent is expected to be effective even by oral administration.